Publications by authors named "D E Carballo"
The year 2024 has seen significant progress in the management of heart failure. New treatments have demonstrated their efficacy, particularly for heart failure with preserved ejection fraction, cardiac amyloidosis, and hypertrophic cardiomyopathy. Advances in imaging, such as MRI and PET-CT, highlight the growing integration of innovative technologies and artificial intelligence in cardiology for diagnosing complex cardiovascular diseases.
View Article and Find Full Text PDFObjectives: To assess the association between the intensity of statin therapy and the level of physical activity in patients 1 year after an acute coronary syndrome (ACS).
Design: Prospective cohort study from the Special Program University Medicine-Acute Coronary Syndromes.
Setting: Four university hospital centres in Switzerland.
Aims: The benefit of long-term beta-blocker therapy after acute coronary syndromes (ACS) without heart failure in the reperfusion era is uncertain. Two recent randomized trials found conflicting results. The present study assessed the safety of beta-blocker discontinuation within 12 months following ACS with LVEF ≥40%.
View Article and Find Full Text PDFArticle Synopsis
- The study assessed eligibility for marine omega-3 fatty acid eicosapentaenoic acid (EPA) supplementation in patients with acute coronary syndromes (ACS) in a Swiss cohort, as recommended by 2019 European Society of Cardiology guidelines.
- Out of 2643 patients, 32% were eligible for EPA supplementation one year post-ACS, with higher eligibility rates found in younger individuals, smokers, diabetics, hypertensive patients, and the obese.
- The research indicates that statins and other lipid-lowering therapies could reduce the percentage of these patients eligible for omega-3 supplementation, suggesting a need to address residual cardiovascular risk in those with hypertriglyceridemia.
Background: Long-term control of cardiovascular risk factors after acute coronary syndrome (ACS) is the cornerstone for preventing recurrence. We investigated the extent of cardiovascular risk factor management in males and females with and without familial hypercholesterolemia (FH) 5 years after ACS.
Methods: We studied patients hospitalized for ACS between 2009 and 2017 in a Swiss multicenter prospective cohort study.